Literature DB >> 14625214

Gray matter N-acetyl aspartate deficits in secondary progressive but not relapsing-remitting multiple sclerosis.

Elfar Adalsteinsson1, Annette Langer-Gould, Ronald J Homer, Archana Rao, Edith V Sullivan, Christiane Abbehusen Lima, Adolf Pfefferbaum, Scott W Atlas.   

Abstract

BACKGROUND AND
PURPOSE: Spectroscopic examination of multiple sclerosis (MS) patients has revealed abnormally low N-acetyl-aspartate (NAA) signal intensity, even in brain tissue that appears normal on high-resolution structural MR images but has yielded inconclusive evidence to distinguish the well-documented clinical differences between MS subtypes. This study used proton MR spectroscopic imaging (MRSI) and high-resolution MR imaging to characterize metabolite profiles in normal-appearing brain tissue of relapsing-remitting multiple sclerosis (RRMS) and secondary progressive (SP) MS.
METHODS: Volumetric spiral MRSI was used together with high-resolution MR imaging to derive absolute measures of metabolite concentrations separately in normal-appearing supratentorial cerebral gray matter and white matter in five RRMS patients, five SPMS patients, and nine age-matched controls. Structural MR images were segmented into compartments of gray matter, white matter, CSF, and lesions, and metabolite signals per unit of tissue volume were calculated for gray matter and white matter separately.
RESULTS: Only the SPMS group had significantly lower NAA concentrations in normal-appearing gray matter compared with concentrations in controls. NAA in normal-appearing white matter was equally reduced in RRMS and SPMS patients. The functional relevance of this brain metabolite measure was suggested by the observed but statistically nonsignificant correlation between higher disability scores on the Expanded Disability Status Scale and lower gray matter NAA concentrations.
CONCLUSION: The otherwise occult abnormality in supratentorial gray matter in SPMS but not RRMS may explain the more severe physical and cognitive impairments afflicting patients with SPMS that do not correlate well with visible lesion burden.

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 14625214      PMCID: PMC8148912     

Source DB:  PubMed          Journal:  AJNR Am J Neuroradiol        ISSN: 0195-6108            Impact factor:   3.825


  33 in total

1.  Longitudinal decline of the neuronal marker N-acetyl aspartate in Alzheimer's disease.

Authors:  E Adalsteinsson; E V Sullivan; N Kleinhans; D M Spielman; A Pfefferbaum
Journal:  Lancet       Date:  2000-05-13       Impact factor: 79.321

2.  Regularized higher-order in vivo shimming.

Authors:  Dong-Hyun Kim; Elfar Adalsteinsson; Gary H Glover; Daniel M Spielman
Journal:  Magn Reson Med       Date:  2002-10       Impact factor: 4.668

3.  Inflammatory CNS demyelination: histopathologic correlation with in vivo quantitative proton MR spectroscopy.

Authors:  A Bitsch; H Bruhn; V Vougioukas; A Stringaris; H Lassmann; J Frahm; W Brück
Journal:  AJNR Am J Neuroradiol       Date:  1999-10       Impact factor: 3.825

4.  Segmentation of MR brain images into cerebrospinal fluid spaces, white and gray matter.

Authors:  K O Lim; A Pfefferbaum
Journal:  J Comput Assist Tomogr       Date:  1989 Jul-Aug       Impact factor: 1.826

5.  New diagnostic criteria for multiple sclerosis: guidelines for research protocols.

Authors:  C M Poser; D W Paty; L Scheinberg; W I McDonald; F A Davis; G C Ebers; K P Johnson; W A Sibley; D H Silberberg; W W Tourtellotte
Journal:  Ann Neurol       Date:  1983-03       Impact factor: 10.422

6.  Rate dependence of regional cerebral activation during performance of a repetitive motor task: a PET study.

Authors:  M Blinkenberg; C Bonde; S Holm; C Svarer; J Andersen; O B Paulson; I Law
Journal:  J Cereb Blood Flow Metab       Date:  1996-09       Impact factor: 6.200

7.  Relapses and progression of disability in multiple sclerosis.

Authors:  C Confavreux; S Vukusic; T Moreau; P Adeleine
Journal:  N Engl J Med       Date:  2000-11-16       Impact factor: 91.245

8.  Localized (1)H magnetic resonance spectroscopy in mainly cortical gray matter of patients with multiple sclerosis.

Authors:  P Sarchielli; O Presciutti; R Tarducci; G Gobbi; A Alberti; G P Pelliccioli; P Chiarini; V Gallai
Journal:  J Neurol       Date:  2002-07       Impact factor: 4.849

9.  Rating neurologic impairment in multiple sclerosis: an expanded disability status scale (EDSS).

Authors:  J F Kurtzke
Journal:  Neurology       Date:  1983-11       Impact factor: 9.910

10.  Evaluation of multiple sclerosis by 1H spectroscopic imaging at 4.1 T.

Authors:  J W Pan; H P Hetherington; J T Vaughan; G Mitchell; G M Pohost; J N Whitaker
Journal:  Magn Reson Med       Date:  1996-07       Impact factor: 4.668

View more
  16 in total

Review 1.  MR spectroscopy and spectroscopic imaging of the brain.

Authors:  He Zhu; Peter B Barker
Journal:  Methods Mol Biol       Date:  2011

Review 2.  MRI evidence for multiple sclerosis as a diffuse disease of the central nervous system.

Authors:  Massimo Filippi; Maria Assunta Rocca
Journal:  J Neurol       Date:  2005-11       Impact factor: 4.849

3.  Neurologic 3D MR spectroscopic imaging with low-power adiabatic pulses and fast spiral acquisition.

Authors:  Ovidiu C Andronesi; Borjan A Gagoski; A Gregory Sorensen
Journal:  Radiology       Date:  2011-12-20       Impact factor: 11.105

Review 4.  Recent advances in the neuroimaging of multiple sclerosis.

Authors:  William D Rooney; Patricia K Coyle
Journal:  Curr Neurol Neurosci Rep       Date:  2005-05       Impact factor: 5.081

5.  (1)H MR spectroscopy of the brain in multiple sclerosis subtypes with analysis of the metabolite concentrations in gray and white matter: initial findings.

Authors:  Paul E Sijens; Jop P Mostert; Matthijs Oudkerk; Jacques De Keyser
Journal:  Eur Radiol       Date:  2005-07-19       Impact factor: 5.315

6.  The basal ganglia: a substrate for fatigue in multiple sclerosis.

Authors:  N Téllez; J Alonso; J Río; M Tintoré; C Nos; X Montalban; A Rovira
Journal:  Neuroradiology       Date:  2007-10-23       Impact factor: 2.804

7.  Relationships between gray matter metabolic abnormalities and white matter inflammation in patients at the very early stage of MS : a MRSI study.

Authors:  My Van Au Duong; Bertrand Audoin; Yann Le Fur; Sylviane Confort-Gouny; Irina Malikova; Elisabeth Soulier; Patrick Viout; André Ali-Cherif; Jean Pelletier; Patrick J Cozzone; Jean-Philippe Ranjeva
Journal:  J Neurol       Date:  2007-04-20       Impact factor: 4.849

Review 8.  Proton magnetic resonance spectroscopy in multiple sclerosis.

Authors:  Balasrinivasa R Sajja; Jerry S Wolinsky; Ponnada A Narayana
Journal:  Neuroimaging Clin N Am       Date:  2009-02       Impact factor: 2.264

9.  Quantitative cervical spinal cord 3T proton MR spectroscopy in multiple sclerosis.

Authors:  A F Marliani; V Clementi; L Albini Riccioli; R Agati; M Carpenzano; F Salvi; M Leonardi
Journal:  AJNR Am J Neuroradiol       Date:  2009-09-03       Impact factor: 3.825

10.  MR spectroscopy (MRS) and magnetisation transfer imaging (MTI), lesion load and clinical scores in early relapsing remitting multiple sclerosis: a combined cross-sectional and longitudinal study.

Authors:  J Bellmann-Strobl; H Stiepani; J Wuerfel; G Bohner; F Paul; C Warmuth; O Aktas; K P Wandinger; F Zipp; R Klingebiel
Journal:  Eur Radiol       Date:  2009-03-24       Impact factor: 5.315

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.